Geoffrey Stephens, PhD, MBA

Digitizing Chef Intuition in Cell Therapy

Science EN ↓ 3 episodes

AiCella, Inc., led by CEO Geoffrey Stephens, is leveraging artificial intelligence to transform the complex field of cell and gene therapy manufacturing. By utilizing their proprietary Insights platform, the company aims to resolve production bottlenecks and lower the high costs currently associated with these life-saving treatments. The technical framework incorporates a variety of machine learning algorithms and deep learning models to predict manufacturing outcomes and improve the quality of products like CAR-T and iPSC cells.

Author

Geoffrey Stephens, PhD, MBA

Episodes

AI-Driven Nondestructive Assessment of iPSC Pluripotency and Manufacturing Outputs 27.05.2026 21:09

Here, we explore the integration of artificial intelligence and machine learning into the complex field of cell and gene therapy manufacturing . We highlight the Insights™ platform , which harmonizes diverse data streams to create predictive models that enhance production efficiency and product quality, and demonstrate how deep learning can non-destructively evaluate stem cell pluripote...

Stopping AI Hallucinations in CGT Manufacturing 27.05.2026 22:08

The AiCella Insights platform introduces a manufacturing-aware RAG framework designed to unify fragmented data within the cell and gene therapy (CGT) sector. This specialized AI system addresses the limitations of generic large language models by grounding its responses in proprietary internal records , ensuring both factual accuracy and full audibility . The process involves standardizing...

Overcoming the "Chefs Cooking Soup" Mentality 27.05.2026 21:20

Through case studies involving predictive modeling and automated image assessment , the sources demonstrate how data-driven workflows can identify critical production factors. Ultimately, this AI-driven approach seeks to accelerate decision-making and optimize biological processes to significantly enhance patient outcomes .